:: Altroz - News Magazine HTML Template ::

Language:

farabursen News

Novartis AG Announces Groundbreaking $1.7B Acquisition of Regulus Therapeutics to Revolutionize ADPKD Treatment

James Carter 01 May, 2025

Novartis AG is set to acquire Regulus Therapeutics in a deal worth up to $1.7B, aiming to advance the treatment for ADPKD through the development of farabursen, with the transactio...

Business

Novartis AG Set to Acquire Regulus Therapeutics in a Groundbreaking $1.7 Billion Deal

Michael Lee 01 May, 2025

Novartis AG announces a strategic acquisition of Regulus Therapeutics Inc. for up to $1.7 billion, aiming to bring innovative treatments like farabursen to patients with ADPKD. The...